JPMorgan raised the firm’s price target on Medtronic (MDT) to $100 from $90 and keeps a Neutral rating on the shares ahead of the fiscal Q2 report.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDT:
- 3 Best Dividend Aristocrat Stocks to Buy Now, 11/06/2025
- Medtronic Announces Executive Vice President’s Retirement
- Medtronic announces CMS finalizes coverage determination on renal denervation
- Medtronic’s Promising RDN Trial Results and Market Growth Potential Drive Buy Rating
- Medtronic’s Symplicity Spyral System: A Promising Growth Opportunity with Proven Efficacy